ICU MEDICAL INC/DE (ICUI): Results of Operations and Financial Condition
ICU MEDICAL INC/DE (ICUI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991q22026er.htm EX-99.1 Document Exhibit 99.1 ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance SAN CLEMENTE, Calif., August 6, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufa
How this was made
The 30-second read
Why it matters
The company updated FY 2026 GAAP net income, GAAP diluted EPS, Adjusted EBITDA, and diluted EPS guidance, providing a new earnings framework for traders and analysts.
Market read
This is a primary-source earnings and guidance update, with specific GAAP and non-GAAP ranges that can drive repricing and positioning ahead of subsequent quarters.
What to watch
Vital Care product line revenue fell sharply year over year, and the company’s forward-looking risk list highlights supply-chain concentration and integration/divestiture execution risks that could pressure future quarters.
Background
ICU Medical’s Q2 2026 comparisons reflect the May 1, 2025 divestiture of the IV Solutions business, with organic revenue growth excluding divestiture and FX impacts.
Ticker impact
ICU Medical reported Q2 2026 results and updated FY 2026 guidance, including GAAP net income and Adjusted EBITDA ranges.
Near-term bias higher as traders reprice FY 2026 earnings and EBITDA expectations; watch for sensitivity to the GAAP net income range widening/narrowing.
The filing provides fresh, specific quarterly datapoints (revenue, gross margin, net income, adjusted EPS/EBITDA) plus updated full-year GAAP and non-GAAP guidance ranges, which are direct inputs to valuation and positioning.
Market effects
Infusion systems and critical care suppliers may see read-across demand and margin expectations if peers are also normalizing post-divestiture portfolio effects.
Limited direct regional spillover; primarily US healthcare medtech sentiment.
Moderate, as guidance updates can influence broader hospital supply chain and medtech earnings expectations.
Counterpoint
GAAP net income declined year over year, so the headline profitability improvement may be driven by non-GAAP adjustments and portfolio effects rather than durable operating leverage.
Key entities
- issuerICU Medical, Inc.
Nasdaq-listed medical products company reporting Q2 2026 results and updating FY 2026 guidance via SEC 8-K.
- executiveVivek Jain
CEO quoted stating Q2 results were ahead of expectations for Infusion Systems and generally in line for the remainder.
